Seattle Biotech Startup Deverra Therapeutics Raising Cash to Develop Cellular Immunotherapies

Deverra Therapeutics, a biotech startup based in Seattle, has raised $2.4 million to support its immunotherapy platform, according to a recent SEC filing.

With the primary goal of creating “a stem cell expansion and directed-differentiation platform,” Deverra began in 2019 with a license from Fred Hutchinson Cancer Research Center. The company is backed by extensive government research and is led by founder and CEO Colleen Delaney.

The recent funding follows a $3.5 million grant Deverra received earlier this year from the Andy Hill CARE Fund. Sorrento Therapeutics, a California-based biotech company, also invested more than $10 million in Deverra in 2019.